Sanofi-Aventis today said the U.S. District for the Central District of California ruled against the company in its suit over Lovenox, a popular drug to treat blood clots.
S-A said it is evaluating options regarding further legal recourse. While several companies have requested marketing approvals for generic versions of Lovenox, Sanofi said it's not learned to date of any that have received approval from the Food and Drug Administration.
Lovenox was the company's top revenue producer, generating nine-month sales of 1.82 billion euros ($2.4 billion).
Lovenox is derived from a pig's intestines, making it more complicated to produce an equivalent drug than just replicating a chemical formula.
"Generic (fully substitutable) versions of Lovenox are unlikely in our view, given the FDA's recently cautious stance on substitutable versions of growth hormone," said Paul Mann, an analyst at Deutsche Bank.
Subscribe via RSS
